Innoviva ROE 2012-2025 | INVA
Current and historical return on equity (ROE) values for Innoviva (INVA) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Innoviva ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2025-12-31 | $0.27B | $1.17B | 30.58% |
| 2025-09-30 | $0.13B | $1.01B | 16.59% |
| 2025-06-30 | $0.04B | $0.72B | 5.58% |
| 2025-03-31 | $-0.06B | $0.65B | -9.13% |
| 2024-12-31 | $0.02B | $0.69B | 3.37% |
| 2024-09-30 | $0.07B | $0.67B | 9.58% |
| 2024-06-30 | $0.15B | $0.67B | 21.86% |
| 2024-03-31 | $0.18B | $0.70B | 28.43% |
| 2023-12-31 | $0.18B | $0.68B | 29.78% |
| 2023-09-30 | $0.05B | $0.63B | 8.66% |
| 2023-06-30 | $0.23B | $0.56B | 40.29% |
| 2023-03-31 | $0.23B | $0.56B | 40.12% |
| 2022-12-31 | $0.22B | $0.57B | 37.01% |
| 2022-09-30 | $0.29B | $0.64B | 51.31% |
| 2022-06-30 | $0.10B | $0.57B | 18.55% |
| 2022-03-31 | $0.19B | $0.55B | 38.09% |
| 2021-12-31 | $0.27B | $0.53B | 50.26% |
| 2021-09-30 | $0.31B | $0.49B | 56.41% |
| 2021-06-30 | $0.27B | $0.39B | 47.45% |
| 2021-03-31 | $0.25B | $0.70B | 43.38% |
| 2020-12-31 | $0.22B | $0.61B | 43.88% |
| 2020-09-30 | $0.22B | $0.54B | 48.65% |
| 2020-06-30 | $0.23B | $0.49B | 59.80% |
| 2020-03-31 | $0.19B | $0.41B | 59.11% |
| 2019-12-31 | $0.16B | $0.34B | 58.90% |
| 2019-09-30 | $0.38B | $0.28B | 168.99% |
| 2019-06-30 | $0.38B | $0.25B | 307.63% |
| 2019-03-31 | $0.40B | $0.20B | 1666.67% |
| 2018-12-31 | $0.40B | $0.16B | -499.68% |
| 2018-09-30 | $0.19B | $-0.11B | -105.70% |
| 2018-06-30 | $0.17B | $-0.16B | -80.10% |
| 2018-03-31 | $0.15B | $-0.21B | -60.25% |
| 2017-12-31 | $0.13B | $-0.24B | -48.86% |
| 2017-09-30 | $0.10B | $-0.22B | -33.47% |
| 2017-06-30 | $0.09B | $-0.30B | -27.22% |
| 2017-03-31 | $0.07B | $-0.33B | -20.31% |
| 2016-12-31 | $0.06B | $-0.35B | -16.32% |
| 2016-09-30 | $0.04B | $-0.37B | -10.58% |
| 2016-06-30 | $0.02B | $-0.36B | -5.18% |
| 2016-03-31 | $-0.01B | $-0.36B | 1.51% |
| 2015-12-31 | $-0.02B | $-0.34B | 6.56% |
| 2015-09-30 | $-0.04B | $-0.32B | 14.55% |
| 2015-06-30 | $-0.06B | $-0.29B | 23.09% |
| 2015-03-31 | $-0.11B | $-0.26B | 51.85% |
| 2014-12-31 | $-0.17B | $-0.22B | 198.24% |
| 2014-09-30 | $-0.20B | $-0.19B | -448.62% |
| 2014-06-30 | $-0.23B | $-0.19B | -130.11% |
| 2014-03-31 | $-0.20B | $0.26B | -82.21% |
| 2013-12-31 | $-0.17B | $0.30B | -84.26% |
| 2013-09-30 | $-0.15B | $0.33B | -91.10% |
| 2013-06-30 | $-0.14B | $0.09B | -109.88% |
| 2013-03-31 | $-0.14B | $0.09B | -91.95% |
| 2012-12-31 | $-0.02B | $0.16B | -13.77% |
| 2012-09-30 | $-0.02B | $0.17B | -34.16% |
| 2012-06-30 | $-0.02B | $0.19B | -163.27% |
| 2012-03-31 | $-0.01B | $0.01B | 18.08% |
| 2011-12-31 | $-0.12B | $-0.09B | 219.91% |
| 2011-09-30 | $-0.10B | $-0.06B | 268.49% |
| 2011-06-30 | $-0.09B | $-0.04B | 154.39% |
| 2011-03-31 | $-0.08B | $-0.03B | 105.99% |
| 2010-12-31 | $-0.08B | $-0.02B | 83.58% |
| 2010-09-30 | $-0.09B | $-0.14B | 61.16% |
| 2010-06-30 | $-0.09B | $-0.13B | 58.37% |
| 2010-03-31 | $-0.09B | $-0.11B | 55.97% |
| 2009-12-31 | $-0.09B | $-0.19B | 50.97% |
| 2009-09-30 | $-0.08B | $-0.18B | 51.55% |
| 2009-06-30 | $-0.08B | $-0.16B | 55.42% |
| 2009-03-31 | $-0.08B | $-0.14B | 64.34% |
| 2008-12-31 | $-0.09B | $-0.14B | 81.21% |
| 2008-09-30 | $-0.11B | $-0.13B | 112.69% |
| 2008-06-30 | $-0.12B | $-0.11B | 157.42% |
| 2008-03-31 | $-0.14B | $-0.09B | 261.68% |
| 2007-12-31 | $-0.16B | $-0.07B | 617.48% |
| 2007-09-30 | $-0.16B | $-0.04B | -2523.08% |
| 2007-06-30 | $-0.17B | $-0.02B | -422.36% |
| 2007-03-31 | $-0.17B | $0.02B | -219.14% |
| 2006-12-31 | $-0.17B | $0.06B | -150.57% |
| 2006-09-30 | $-0.17B | $0.09B | -155.25% |
| 2006-06-30 | $-0.17B | $0.13B | -153.85% |
| 2006-03-31 | $-0.16B | $0.16B | -143.11% |
| 2005-12-31 | $-0.14B | $0.06B | -126.27% |
| 2005-09-30 | $-0.13B | $0.10B | -89.19% |
| 2005-06-30 | $-0.11B | $0.13B | -76.90% |
| 2005-03-31 | $-0.11B | $0.16B | -97.60% |
| 2004-12-31 | $-0.10B | $0.19B | -136.91% |
| 2004-09-30 | $-0.09B | $0.11B | -333.33% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.697B | $0.359B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| Johnson & Johnson (JNJ) | United States | $586.690B | 22.54 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Pfizer (PFE) | United States | $156.812B | 8.54 |
| Sanofi (SNY) | France | $112.219B | 10.39 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |